MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX

Bevacizumab is a humanized anti-vascular endothelial growth factor monoclonal antibody, used in combination with a oxaliplatin-based chemotherapy in the treatment of metastatic colorectal cancer (mCRC). The aim of the present study was to identify microRNA (miRNA)-based predictive biomarkers of ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiss, I., Mlčochová, J., Součková, K., Fabian, P., Poprach, A., Halamkova, J., Svoboda, M., Vyzula, R., Slaby, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494676/
https://www.ncbi.nlm.nih.gov/pubmed/28693229
http://dx.doi.org/10.3892/ol.2017.6255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494676/
https://www.ncbi.nlm.nih.gov/pubmed/28693229
http://dx.doi.org/10.3892/ol.2017.6255

Ejemplares similares